CN107106528A - 使用丝氨酸治疗或预防炎症 - Google Patents
使用丝氨酸治疗或预防炎症 Download PDFInfo
- Publication number
- CN107106528A CN107106528A CN201680004922.7A CN201680004922A CN107106528A CN 107106528 A CN107106528 A CN 107106528A CN 201680004922 A CN201680004922 A CN 201680004922A CN 107106528 A CN107106528 A CN 107106528A
- Authority
- CN
- China
- Prior art keywords
- inflammation
- composition
- disease
- serine
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 53
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 53
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 57
- 206010009887 colitis Diseases 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims description 24
- 235000016709 nutrition Nutrition 0.000 claims description 20
- 230000035764 nutrition Effects 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 230000003405 preventing effect Effects 0.000 claims description 9
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 235000013373 food additive Nutrition 0.000 claims description 7
- 239000002778 food additive Substances 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000021323 fish oil Nutrition 0.000 claims description 6
- 235000012054 meals Nutrition 0.000 claims description 5
- 235000013406 prebiotics Nutrition 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000012657 Atopic disease Diseases 0.000 claims description 4
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 206010031149 Osteitis Diseases 0.000 claims description 4
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 4
- 208000000474 Poliomyelitis Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000038016 acute inflammation Diseases 0.000 claims description 4
- 230000006022 acute inflammation Effects 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 208000018339 bone inflammation disease Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 201000002491 encephalomyelitis Diseases 0.000 claims description 4
- 206010014801 endophthalmitis Diseases 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000036473 myasthenia Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 206010043778 thyroiditis Diseases 0.000 claims description 4
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000013459 approach Methods 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 208000009326 ileitis Diseases 0.000 claims 3
- 239000006041 probiotic Substances 0.000 claims 2
- 235000018291 probiotics Nutrition 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 235000019197 fats Nutrition 0.000 description 11
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- -1 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000011868 grain product Nutrition 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000015116 cappuccino Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 235000019722 synbiotics Nutrition 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 description 1
- GTBJRWFFEQJCHN-REOHCLBHSA-N (2s)-3-hydroxy-2-(hydroxyamino)propanoic acid Chemical compound OC[C@H](NO)C(O)=O GTBJRWFFEQJCHN-REOHCLBHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000594011 Leuciscus leuciscus Species 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- CNIUEVQJABPUIJ-QMMMGPOBSA-N N-hydroxytyrosine Chemical compound ON[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNIUEVQJABPUIJ-QMMMGPOBSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010072574 Periodontal inflammation Diseases 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000020248 camel milk Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000021577 malt beverage Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 235000020265 peanut milk Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
Abstract
本发明提供了使用丝氨酸治疗或预防炎症的方法和组合物。向患有炎症或处于炎症风险中的个体如人或其它哺乳动物施用治疗有效量的丝氨酸。所述方法和组合物可控制和/或减轻身体的炎症反应，诸如结肠炎。
Description
背景技术
本公开整体涉及健康与营养。更具体地，本公开涉及用于使用丝氨酸治疗或预防炎症的方法和组合物。
炎症是复杂的先天免疫系统反应，涉及白细胞和血浆蛋白在感染、毒素暴露或细胞损伤部位的积累和活化。虽然炎症在控制感染和促进组织修复方面具有保护功能，但炎症也可能导致组织损伤和疾病。胃肠疾病诸如炎性肠病(例如克罗恩病、溃疡性结肠炎和囊炎)、食物过敏、和由食物过敏引起的特应性皮炎总是伴有不同程度的异常肠道炎症应答。已经提出，通过平衡促炎细胞因子和抗炎细胞因子或诱导调节性细胞因子来减轻该肠道炎症是对这些慢性疾病的可能治疗。存在许多此类细胞因子，其中例如IFN-γ、IL1、IL8、IL12和TNF-α被认为是促炎症的，并且例如IL10和TGF-β被认为是抗炎的。
不期望的炎症可通过正确药物治疗。然而，药物可能会导致不良副作用，并且经常需要医务人员的监督。一些营养干预措施，诸如使用n-3多不饱和脂肪酸(PUFA)实现炎症细胞功能下降，并且减少细胞介导的免疫应答(如淋巴细胞增殖和NK活性)，这可能导致对宿主防御的潜在有害影响。
发明内容
本公开提供了用于治疗或预防炎症的方法，该方法包括向对其有需要或处于其风险中的个体施用丝氨酸。据本发明人的最新知识，迄今为止在丝氨酸与炎症之间尚无明确的联系。本发明人惊奇地发现，大鼠模型中，在饮食中补充丝氨酸，减少了结肠炎。
因此，在一般实施方案中，提供了用于治疗炎症的方法。该方法包括向患有炎症的个体施用包含治疗有效量的丝氨酸的组合物。在另一个实施方案中，提供了用于预防炎症的方法。该方法包括向处于其风险中的个体施用包含治疗有效量的丝氨酸的组合物。在另一个实施方案中，提供了用于治疗或预防结肠炎的方法。该方法包括向对其有需要或处于其风险中的个体施用包含治疗有效量的丝氨酸的组合物。结肠炎可为急性结肠炎和/或慢性结肠炎。在另一个实施方案中，提供了用于治疗炎性肠病(IBD)的方法。该方法包括向对其有需要的个体施用包含治疗有效量的丝氨酸的组合物。在另一个实施方案中，提供了用于预防或推迟IBD患者复发的方法。该方法包括向对其有需要的个体施用包含治疗有效量的丝氨酸的组合物。IBD可为克罗恩病或溃疡性结肠炎。
在一个实施方案中，所述组合物通过选自口服、局部、肠道和肠胃外的途径施用。
在一个实施方案中，所述组合物为医疗食物。在一个实施方案中，所述组合物为选自以下的形式：营养全面的产品、饮料、饮食补充剂、代餐、食品添加剂、食物产品补充剂、用于溶解的粉末、肠道营养产品、婴儿配方产品、以及它们的组合。在一个实施方案中，所述组合物为选自以下的形式：乳制品、冷冻饮料、架藏稳定的饮料、汤、营养棒、糖果(confectionery)、乳制品、可发酵乳制品、酸奶、乳基粉、菜泥、谷类产品、发酵谷物制品、冰淇淋、糖果(candy)、饼干、蛋糕、巧克力、热牛奶咖啡、咖啡、宠物食品、宠物饮料、以及它们的组合。
在另一个实施方案中，所述组合物是药物。
在一个实施方案中，所述炎症选自急性炎症、皮肤炎症、炎性肠综合征、肝脏炎症、过敏、特应性疾病、骨炎、类风湿性关节炎、系统性红斑狼疮、Gougerot-Sjogren综合征、莱特尔氏综合征、脊髓灰质炎、皮肌炎、甲状腺炎、巴塞多病、桥本氏病、I型糖尿病、爱迪生氏病、自身免疫性肝炎、乳糜泻、Biermer病、多发性硬化症、肌无力、脑脊髓炎、眼炎、肥胖相关炎症、年龄相关的低度炎症、布劳综合征、阿兹海默病、心血管疾病、动脉粥样硬化、代谢综合征、牙龈炎、牙周炎、以及它们的组合。
在一个实施方案中，所述个体选自婴儿、儿童、青少年、成人和老年人。在优选的实施方案中，所述个体选自成年人和老年人。
在一个实施方案中，所述营养组合物还包含至少一种选自以下的组分：益生元、益生菌、合生元、另外的氨基酸、蛋白质、核苷酸、鱼油、ω-3脂肪酸的非海洋来源、植物营养素、抗氧化剂、以及它们的组合。
在一个实施方案中，施用一定量的所述组合物以提供每天约0.07g至约0.35g的丝氨酸/kg个体体重。
在另一个实施方案中，提供了制备用于治疗或预防炎症的组合物的方法。该方法包括向食品中加入丝氨酸以形成富含丝氨酸的食品。
本公开的优点是提供治疗或预防炎症的方法，并且提供可用于此类方法的组合物。
本公开的另一个优点是，通过口服施用掺入丝氨酸的治疗性营养组合物或药物，来减少或预防炎症。
本公开的另一个优点是，使用具有抗炎性质并且对受治疗者的免疫防御不具有任何有害作用的天然化合物来减少或预防炎症。
本公开的另一个优点是比已知药物更安全地减少或预防炎症。
本公开的另一个优点是减少或预防炎症，具有可耐受的副作用或不具有副作用。
本文描述了另外的特征和优点，并且根据以下具体实施方式和附图，这些特征和优点将显而易见。
附图说明
图1示出丝氨酸的化学结构。
图2为本文所公开的实施例的实验结果图示。
具体实施方式
如在本公开和所附权利要求中所用，单数形式“一个”、“一种”和“所述”包括复数指代物，除非上下文另外明确规定。因此，例如，对“一种氨基酸”或“所述氨基酸”的标引包括两种或更多种氨基酸。在“X和/或Y”的上下文中使用的术语“和/或”应被解释为“X”或“Y”或“X和Y”。当在本文中使用时，尤其是后跟一列术语时，术语“示例”仅是示例性和例示性的，并且不应被视为排他性或全面性的。
如本文所用，“约”应理解为是指某一数值范围内的数字，例如该所提及数字的-10％至+10％，优选地在该所提及数字的-5％至+5％的范围内，更优选地在该所提及数字的-1％至+1％的范围内，最优选地在该所提及数字的-0.1％至+0.1％的范围内。此外，本文中的所有数值范围都应理解为包含该范围内的所有整数或分数。另外，这些数值范围应理解为对涉及该范围内任何数值或数值子集的权利要求提供支持。例如，1至10的公开应理解为支持1至8、3至7、1至9、3.6至4.6、3.5至9.9等的范围。
本文中表示的所有百分数均以占组合物总重量的重量计，除非另有表示。提及pH时，其值对应于使用标准设备在25℃下测量的pH。
术语“病症”和“障碍”意指任何疾病、病症、症状或适应症。如本文所用，“有效量”是预防缺陷、治疗个体病症或障碍的量，或更一般地讲，是减轻症状，管理病症或障碍进展或向个体提供营养、生理或医疗有益效果的量。
术语“治疗(treatment/treating)”包括导致病症或障碍改善，例如减轻、减少、调节或消除病症或障碍的任何效果。“治疗(treating/treatment of)”病症或障碍的非限制性示例包括：(1)抑制病症或障碍，即阻止病症或障碍或其临床症状的发展，以及(2)缓解病症或障碍，即，使病症或障碍或其临床症状暂时或永久地消退。术语“治疗(treating/treatment)”既包括预防性或防止性治疗(预防和/或延缓目标病理学病症或障碍的发展)，也包括治愈性、治疗性或疾病改善性治疗，包括治愈、延缓、减轻已确诊病理学病症或障碍的症状和/或中断其进展的治疗性措施；和治疗存在染病风险或怀疑已染病的患者，以及治疗患病或已经诊断为罹患疾病或医学病症的患者。所述术语不一定表示个体被治疗直至完全恢复。治疗可与患者或医生相关。
术语“预防(prevention/preventing)”是指使得所提及的病症或障碍的临床症状不在可能暴露于或易患上该病症或障碍但尚未经历或表现出该病症或障碍的症状的个体中发展。“预防”包括降低病症或障碍的风险和/或严重程度。
“动物”包括但不限于哺乳动物，所述哺乳动物包括但不限于啮齿动物，水栖哺乳动物，家畜诸如狗和猫，和农畜诸如羊、猪、牛和马，以及人。在使用“动物”、“哺乳动物”或其复数形式时，这些术语还适用于能够具有通过段落上下文表现出的或意欲表现出的作用的任何动物。如本文所用，术语“患者”和“个体”应被理解为包括接受或意欲接受治疗如本文所定义治疗的动物，尤其是哺乳动物，还更尤其是人。虽然本文中常用术语“个体”和“患者”来指人，但本公开并非限制于此。因此，术语“个体”和“患者”是指可受益于治疗的任何动物、哺乳动物或人。
如果动物的年龄超过其出生地平均预期寿命的三分之二，优选地超过其出生地平均预期寿命的四分之三，更最优选地超过其出生地平均预期寿命的五分之四，那么就认为该动物为“老年”。“老年人”是指实际年龄为65岁或更大的人。
如本文所用，“长期施用”是持续施用(例如每周至少两次，优选每日)6周或更长时间。“短期施用”是持续施用(例如每周至少两次，优选每日)不到6周。
术语“食物”、“食物产品”和“食物组合物”意指旨在供人摄入并且向人提供至少一种营养物质的产品或组合物。本文所公开的组合物可不含本文未具体公开的任何要素。因此，使用术语“包括/包含”的实施方案的公开内容包括“基本上由所指明的组分组成”的实施方案和“由所指明的组分组成”的实施方案的公开内容。类似地，本文所公开的方法可不含本文没有具体描述的任何步骤。因此，使用术语“包括/包含”的实施方案的公开内容包括“基本上由所指明的步骤组成”的实施方案和“由所指明的步骤组成”的实施方案的公开内容。本文所公开的任何实施方案可与本文所公开的任何其它实施方案组合。
参考附图，图1示出了丝氨酸的化学结构。丝氨酸是非芳族羟基极性(无电荷)氨基酸。丝氨酸被归类为哺乳动物的非必需氨基酸，因为它可从必需氨基酸或其它复杂含氮来源内源性合成。
在本公开的一方面，提供了治疗炎症的方法。该方法包括向患有炎症的个体施用包含治疗有效量的丝氨酸的组合物。在本公开的另一方面，提供了预防炎症的方法。该方法包括向处于其风险中的个体施用治疗有效量的丝氨酸。在本公开的另一方面，提供了控制和/或缓解身体炎症反应的方法。该方法包括向患有身体炎症反应的个体施用治疗有效量的丝氨酸。
可将所述组合物施用于人或动物诸如伴侣动物、宠物或牲畜。在一个实施方案中，施用一定量的所述组合物以提供每天约0.07g至约0.35g的丝氨酸/kg体重。所述组合物对任何年龄组均具有有益效果。优选地，所述组合物旨在用于婴儿、幼儿、成年人或老年人。然而，所述组合物可施用于怀孕和/或哺乳期的母亲，以治疗婴儿。所述组合物可以向个体施用，短期施用或长期施用。优选地，所述组合物为肠道施用，例如口服施用。
可通过本文公开的方法和组合物治疗或预防的炎性病症的非限制性示例包括但不限于急性炎症诸如败血病，感染，烧伤和慢性炎症诸如炎性肠病，克罗恩病，溃疡性结肠炎，炎性肠道综合征，坏死性小肠结肠炎，皮肤炎症诸如紫外线或化学诱导的皮肤炎症，湿疹，反应性皮肤病，牛皮癣，白癜风，痤疮，肝脏炎症，酒精性肝硬化，变态反应，特应性疾病，骨炎，类风湿性关节炎，系统性红斑狼疮，Gougerot-Sjogren综合征，莱特尔氏综合征，脊髓灰质炎，皮肌炎，甲状腺炎，巴塞多病，桥本氏病，I型糖尿病，爱迪生氏病，自身免疫性肝炎，乳糜泻，Biermer病，多发性硬化症，肌无力，脑脊髓炎，眼炎，肥胖相关炎症，年龄相关的低度炎症，布劳综合征，阿兹海默病，心血管疾病，动脉粥样硬化，代谢综合征，牙龈炎，牙周炎，以及它们的组合。
在一个实施方案中，所述组合物包含另外的氨基酸，所述另外的氨基酸选自丙氨酸、精氨酸、天冬酰胺、天冬氨酸、瓜氨酸、半胱氨酸、谷氨酸、谷氨酰胺、甘氨酸、组氨酸、羟脯氨酸、羟丝氨酸、羟酪氨酸、羟赖氨酸、异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、脯氨酸、丝氨酸、牛磺酸、苏氨酸、色氨酸、酪氨酸、缬氨酸、以及它们的组合。在一个实施方案中，所述组合物可另外包含氨基酸前体。在一个实施方案中，所述组合物包含选自半胱氨酸前体胱硫醚、N-乙酰半胱氨酸和/或DACE的氨基酸前体。在另一个实施方案中，所述丝氨酸是所述组合物中唯一的氨基酸。
所述组合物中的丝氨酸可为游离形式(即单体)，或可为二肽、三肽或多肽(例如，本文所用的蛋白质是指具有20个或更多个氨基酸的多肽)的一部分。
所述组合物可为食物产品、食物产品补充剂、动物食物产品、或药物组合物。例如，所述产品可为营养组合物、营养制品、饮料、食品添加剂或药物。食品添加剂或药物可为例如片剂、胶囊、锭剂或液体的形式。食品添加剂或药物优选作为持续释放制剂提供，允许长时间恒定供应丝氨酸。
所述组合物可为医疗食物。医疗食物产品是专门配制的并旨在用于疾病或医学病症的饮食管理(例如，预防或治疗疾病或不期望的医学病症)。医疗食物产品可提供临床营养，例如，满足存在医学病症的患者或具有特定营养需求的其他人士的特殊营养需求。医疗食物产品的形式可以是完全膳食、部分膳食、作为食品添加剂或者用于溶解的粉末。
在一个实施方案中，所述营养组合物为选自片剂、胶囊、液体、咀嚼片、软凝胶，小药囊、粉末、糖浆、液体悬浮液、乳剂、溶液、或它们组合的形式。在一个实施方案中，所述营养组合物为口服营养补充剂。另选地，所述营养组合物可为管饲。
所述组合物可提供全面营养或不全面营养。全面的营养提供充足类型和含量的宏量营养素(蛋白质、脂肪和碳水化合物)和微量营养素，以成为所施用动物的唯一营养来源。患者能够从这类完全营养组合物中得到他们100％的营养需求。不全面营养不能提供充足含量的宏量营养素(蛋白质、脂肪和碳水化合物)或微量营养素，以成为所施用动物的唯一营养来源。优选使用部分或不全面营养组合物作为营养补充剂。
所述组合物优选选自基于乳粉的产品；速溶饮品；即饮型制剂；营养粉末；营养液体；乳基产品，尤其是酸乳酪或冰淇淋；谷类产品；饮料；水；咖啡；热牛奶咖啡；麦芽饮料；巧克力风味饮料；烹饪产品；汤；片剂；和糖浆。乳品可为可从动物或植物来源获得的任何乳品，并且优选为牛乳、人乳、羊乳、山羊乳、马乳、骆驼乳、米浆或豆浆。除此之外或另选地，可使用乳源蛋白质级分或初乳。
所述组合物可包含保护性水性胶体(诸如树胶、蛋白质、改性淀粉)、粘结剂、成膜剂、包囊剂/材料、壁/壳材料、基质化合物、包衣、乳化剂、表面活性试剂、增溶剂(油、脂肪、蜡、卵磷脂等)、吸附剂、载体、填料、共化合物、分散剂、润湿剂、加工助剂(溶剂)、流动剂、掩味剂、增重剂、胶凝剂、凝胶形成剂、抗氧化剂和抗微生物剂。所述组合物还可包含常规的药物添加剂和佐剂、赋形剂和稀释剂，包括但不限于水、任何来源的明胶、植物胶、木质素磺酸盐、滑石、糖、淀粉、阿拉伯树胶、植物油、聚亚烷基二醇、风味剂、防腐剂、稳定剂、乳化剂、缓冲剂、润滑剂、着色剂、润湿剂、填料等。此外，根据政府机构的推荐，所述组合物可包含适用于口服或经肠施用的有机或无机载体材料，以及维生素、矿物质痕量元素和其它微量营养素。
所述组合物可包含蛋白质源、碳水化合物源和/或类脂源。可使用任何适宜的蛋白质源，例如动物蛋白质(诸如乳蛋白、肉蛋白和蛋蛋白)、植物蛋白(诸如大豆蛋白、小麦蛋白、大米蛋白和豌豆蛋白)、游离氨基酸的混合物、或它们的组合。乳蛋白(诸如酪蛋白和乳清)和大豆蛋白是尤其优选的。
如果所述组合物包含脂肪源，则所述脂肪源优选提供所述组合物能量的5％至50％，优选所述能量的10％至40％，更优选20％至30％。植物脂肪诸如大豆油、棕榈油、椰子油、红花油、向日葵油、玉米油、低芥酸菜籽油和卵磷脂是尤其适宜的。如果需要，可包括动物脂肪如乳脂。
碳水化合物源可提供所述组合物能量的20％至80％，优选所述组合物能量的30％至70％。可使用任何合适的碳水化合物，例如蔗糖、乳糖、葡萄糖、果糖、玉米糖浆固体、麦芽糊精及其混合物。如果需要，也可添加膳食纤维。膳食纤维可来自任何适宜的来源，包括例如大豆、豌豆、燕麦、果胶、瓜尔胶、阿拉伯树胶、低聚果糖、低聚半乳糖、唾液乳糖、和源自动物乳的低聚糖。
适宜的维生素和矿物质可包含于所述组合物中。特定维生素和矿物质的存在和量将根据预期的施用受体而变化。
在一个实施方案中，所述组合物还包含一种或多种核苷酸、合生素、鱼油、ω-3脂肪酸的非海洋来源、磷脂、植物营养素和/或抗氧化剂。如本文所用，合生素是益生元和益生菌的组合，其协同改善肠道微生物群。适宜鱼油的非限制性示例包括提供二十二碳六烯酸(DHA)和二十碳五烯酸(EPA)的鱼油。适宜植物营养素的非限制性示例包括槲皮素、姜黄素和柠檬苦素。抗氧化剂是能够减缓或阻止其它分子氧化的分子。适宜抗氧化剂的非限制性示例包括维生素A、类胡萝卜素、维生素C、维生素E、硒、类黄酮、乳枸杞(Lactowolfberry)、枸杞(枸杞子)、多酚、番茄红素、叶黄素、木酚素、辅酶Q10(CoQ10)、橘皮苷和谷胱甘肽。磷脂的非限制性示例包括磷脂酰胆碱、磷脂酰丝氨酸、和磷脂酰乙醇胺。
在本公开的另一方面，提供了制备用于治疗或预防炎症的组合物的方法。该方法包括向食品中加入丝氨酸以形成富含丝氨酸的食品。
实施例
以下非限制性实施例是根据本公开，使用丝氨酸治疗或预防炎症的示例。
实施例1
实验规程按照欧洲实验动物护理和使用指南(指令2010/63/UE)进行。本研究使用来自Janvier(法国)的30只雄性Sprague-Dawley大鼠，年龄为6-8个月，并且在抵达当天重约500/700g。动物被单独饲养在笼子里。研究期间，它们随意自由获得食物和饮用水或葡聚糖硫酸钠(DSS，MW 36-44kDa，ICN Biomedicals)溶液。通过用5％的来自D0至D8的DSS(急性结肠炎)处理大鼠，然后用2％的来自D9至D28的DSS(慢性结肠炎)处理大鼠，诱导结肠炎。将DSS溶解在高压灭菌水中，并且随意提供给大鼠。向对照组动物提供不包含来自D0至D28的DSS的水。
3组大鼠接受以下治疗和饮食：
CTRL组(CTRL-ALA，n＝10)接受对照饮食，所述饮食为由以下组成的干燥半合成粉末(g/kg)：碳水化合物646(小麦淀粉)、蛋白质120(由平衡以满足所有氨基酸需求的鲱鱼餐提供)、类脂64(花生油45、向日葵油10、油菜籽油9)、琼脂-琼脂30、矿物混合物70(UAR205b：CaHPO4，30.1；KCl，7；NaCl，7；MgO，0.735；MgSO4，3.5；Fe2O3，0.21；FeSO47H2O，0.35)和维生素混合物10[UAR 200]。通过补充丙氨酸(10g/kg干物质)，使对照饮食与其它饮食等氮。对照饮食的丝氨酸浓度为5g/kg干物质。
DSS对照组(DSS-ALA，n＝10)接受补充有丙氨酸(10g/kg干物质)的对照饮食。对照饮食的丝氨酸浓度为5g/kg干物质。
DSS组(DSS-SER，n＝10)接受补充有10g/kg(干物质)丝氨酸的对照饮食。
在8d适应期间，向每组大鼠给予它们各自的饮食。从D0开始，它们在如前所述的它们的饮用水中获取或不获取DSS。
在实验结束时(D28)，使用氯胺酮和木脂素的组合麻醉动物，然后通过颈椎脱位处以安乐死。一旦将动物安乐死，就进行腹部中线切口，并且收集回盲部至肛门边缘的结肠。冲洗结肠，收集近端、中间和远端结肠的结肠小块，并且置于冷藏的4％福尔马林中。将样品脱水，然后嵌入蜡中以获得横截面。使用切片进行苏木精-伊红(HE)染色，以评估粘膜变性、粘膜再生和增生、急性和亚急性炎症。最终确定每个结肠部分在各标准下的得分(在0至3范围内)，并且计算总分。
总分示于图2中。与CTRL相比，DSS-ALA组的总结肠炎显著增加(p<0.001)。它在接受丝氨酸补充的DSS组(DSS-SER)中，比在DSS-ALA组中显著更低(p<0.05)。
应当理解，对本文所述的目前优选的实施方案作出的各种改变和修改对于本领域的技术人员将是显而易见的。可在不脱离本发明主题的实质和范围且不削弱其预期优点的前提下作出这些改变和修改。因此，这些改变和修改旨在由所附权利要求书涵盖。
Claims (22)
1.用于治疗炎症的方法，所述方法包括向患有炎症的个体施用包含治疗有效量的丝氨酸的组合物。
2.根据权利要求1所述的方法，其中所述组合物通过选自口服、局部、肠道和肠胃外的途径施用。
3.根据权利要求1所述的方法，其中所述组合物为选自以下的形式：营养全面的产品、饮料、饮食补充剂、代餐、食品添加剂、食物产品补充剂、用于溶解的粉末、肠道营养产品、婴儿配方产品、以及它们的组合。
4.根据权利要求1所述的方法，其中所述炎症选自急性炎症、皮肤炎症、炎性肠病、包括克罗恩病和/或溃疡性结肠炎、炎性肠综合征、肝脏炎症、过敏、特应性疾病、骨炎、类风湿性关节炎、系统性红斑狼疮、Gougerot-Sjogren综合征、莱特尔氏综合征、脊髓灰质炎、皮肌炎、甲状腺炎、巴塞多病、桥本氏病、I型糖尿病、爱迪生氏病、自身免疫性肝炎、乳糜泻、Biermer病、多发性硬化症、肌无力、脑脊髓炎、眼炎、肥胖相关炎症、年龄相关的低度炎症、布劳综合征、阿兹海默病、心血管疾病、动脉粥样硬化、代谢综合征、牙龈炎、牙周炎、以及它们的组合。
5.根据权利要求1所述的方法，其中所述个体选自婴儿、儿童、青少年、成人和老年人。
6.根据权利要求1所述的方法，其中所述营养组合物还包含至少一种选自以下的组分：益生元、益生菌、合生元、另外的氨基酸、蛋白质、核苷酸、鱼油、ω-3脂肪酸的非海洋来源、植物营养素、抗氧化剂、以及它们的组合。
7.根据权利要求1所述的方法，其中施用一定量的所述组合物以提供每天约0.07g至约0.35g的丝氨酸/kg个体体重。
8.用于预防炎症的方法，所述方法包括向处于其风险中的个体施用包含治疗有效量的丝氨酸的组合物。
9.根据权利要求8所述的方法，其中所述组合物通过选自口服、局部、肠道和肠胃外的途径施用。
10.根据权利要求8所述的方法，其中所述组合物为选自以下的形式：营养全面的产品、饮料、饮食补充剂、代餐、食品添加剂、食物产品补充剂、用于溶解的粉末、肠道营养产品、婴儿配方产品、以及它们的组合。
11.根据权利要求8所述的方法，其中所述炎症选自急性炎症、皮肤炎症、炎性肠病、包括克罗恩病和/或溃疡性结肠炎、炎性肠综合征、肝脏炎症、过敏、特应性疾病、骨炎、类风湿性关节炎、系统性红斑狼疮、Gougerot-Sjogren综合征、莱特尔氏综合征、脊髓灰质炎、皮肌炎、甲状腺炎、巴塞多病、桥本氏病、I型糖尿病、爱迪生氏病、自身免疫性肝炎、乳糜泻、Biermer病、多发性硬化症、肌无力、脑脊髓炎、眼炎、肥胖相关炎症、年龄相关的低度炎症、布劳综合征、阿兹海默病、心血管疾病、动脉粥样硬化、代谢综合征、牙龈炎、牙周炎、以及它们的组合。
12.根据权利要求8所述的方法，其中所述个体选自婴儿、儿童、青少年、成人和老年人。
13.根据权利要求8所述的方法，其中所述营养组合物还包含至少一种选自以下的组分：益生元、益生菌、合生元、另外的氨基酸、蛋白质、核苷酸、鱼油、ω-3脂肪酸的非海洋来源、植物营养素、抗氧化剂、以及它们的组合。
14.根据权利要求8所述的方法，其中施用一定量的所述组合物以提供每天约0.07g至约0.35g的丝氨酸/kg个体体重。
15.制备用于治疗或预防炎症的组合物的方法，所述方法包括向食品中加入丝氨酸以形成富含丝氨酸的食品。
16.用于治疗或预防IBD的方法，所述方法包括对其有需要或处于其风险中的个体施用包含治疗有效量的丝氨酸的组合物。
17.用于通过控制炎症来预防或推迟IBD患者复发的方法，所述方法包括向对其有需要或处于其风险中的个体施用包含治疗有效量的丝氨酸的组合物。
18.根据权利要求16或17所述的方法，其中所述IBD为克罗恩病。
19.根据权利要求16或17所述的方法，其中所述IBD为溃疡性结肠炎。
20.用于治疗或预防结肠炎和/或回肠炎的方法，所述方法包括向对其有需要或处于其风险中的个体施用包含治疗有效量的丝氨酸的组合物。
21.根据权利要求20所述的方法，其中所述结肠炎和/或回肠炎是急性的。
22.根据权利要求20所述的方法，其中所述结肠炎和/或回肠炎是慢性的。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152317.2 | 2015-01-23 | ||
| EP15152317 | 2015-01-23 | ||
| PCT/EP2016/051279 WO2016116582A1 (en) | 2015-01-23 | 2016-01-22 | Treatment or prevention of inflammation using serine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107106528A true CN107106528A (zh) | 2017-08-29 |
Family
ID=52394957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680004922.7A Pending CN107106528A (zh) | 2015-01-23 | 2016-01-22 | 使用丝氨酸治疗或预防炎症 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180021278A1 (zh) |
| EP (1) | EP3247345A1 (zh) |
| JP (1) | JP2018504406A (zh) |
| CN (1) | CN107106528A (zh) |
| AU (1) | AU2016208545A1 (zh) |
| CA (1) | CA2973434A1 (zh) |
| WO (1) | WO2016116582A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114364264A (zh) * | 2019-07-19 | 2022-04-15 | 飞滤森有限公司 | 用于癌症治疗和代谢干预疗法的组合物、方法、试剂盒和系统以及其他用途 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| WO2019036471A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
| WO2019048423A1 (en) * | 2017-09-08 | 2019-03-14 | Rigshospitalet | L-SERINE SUPPLEMENTATION IN PREDIABETIC SUBJECTS |
| AR115585A1 (es) | 2018-06-20 | 2021-02-03 | Axcella Health Inc | Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470119A (zh) * | 2009-07-01 | 2012-05-23 | 皮埃尔·法布尔皮肤化妆品公司 | L-丝氨酸作为药物用于预防和/或治疗皮肤炎症应答的用途 |
| CN102573524A (zh) * | 2009-08-21 | 2012-07-11 | N.V.努特里西阿公司 | 调节用于急性期蛋白合成的氨基酸池 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437834A1 (fr) * | 1978-10-04 | 1980-04-30 | Lejeune Jerome | Compositions pharmaceutiques a base de l-serine ou de glycine |
| WO2006049286A1 (ja) * | 2004-11-02 | 2006-05-11 | Ajinomoto Co., Inc. | アレルギー性疾患予防・治療剤 |
| JP2007238581A (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co Ltd | 関節炎改善用組成物 |
-
2016
- 2016-01-22 EP EP16702355.5A patent/EP3247345A1/en not_active Withdrawn
- 2016-01-22 US US15/544,073 patent/US20180021278A1/en not_active Abandoned
- 2016-01-22 JP JP2017537272A patent/JP2018504406A/ja not_active Withdrawn
- 2016-01-22 AU AU2016208545A patent/AU2016208545A1/en not_active Abandoned
- 2016-01-22 WO PCT/EP2016/051279 patent/WO2016116582A1/en active Application Filing
- 2016-01-22 CN CN201680004922.7A patent/CN107106528A/zh active Pending
- 2016-01-22 CA CA2973434A patent/CA2973434A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470119A (zh) * | 2009-07-01 | 2012-05-23 | 皮埃尔·法布尔皮肤化妆品公司 | L-丝氨酸作为药物用于预防和/或治疗皮肤炎症应答的用途 |
| CN102573524A (zh) * | 2009-08-21 | 2012-07-11 | N.V.努特里西阿公司 | 调节用于急性期蛋白合成的氨基酸池 |
Non-Patent Citations (1)
| Title |
|---|
| MAGALI FAURE ET AL: "Specific Amino Acids Increase Mucin Synthesis and Microbiota in Dextran Sulfate Sodium–Treated Rats", 《AMERICAN SOCIETY FOR NUTRITION》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114364264A (zh) * | 2019-07-19 | 2022-04-15 | 飞滤森有限公司 | 用于癌症治疗和代谢干预疗法的组合物、方法、试剂盒和系统以及其他用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180021278A1 (en) | 2018-01-25 |
| JP2018504406A (ja) | 2018-02-15 |
| EP3247345A1 (en) | 2017-11-29 |
| WO2016116582A1 (en) | 2016-07-28 |
| AU2016208545A1 (en) | 2017-06-15 |
| CA2973434A1 (en) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6852980B2 (ja) | 低カロリー高タンパク質の栄養組成物及び該栄養組成物を用いる方法 | |
| JP5421956B2 (ja) | ホエータンパク質組成物、方法及び使用 | |
| ES2269514T3 (es) | Compuesto nutritivo para tratar afecciones inmunologicas. | |
| CN101299934B (zh) | 用于促进追赶生长的营养制剂 | |
| EP2413952B2 (en) | Improvement in promotion of healthy catch-up growth | |
| ES2960750T3 (es) | Oligosacáridos de la leche humana para el tratamiento de infecciones agudas del aparato respiratorio | |
| CN109645320A (zh) | 一种轻断食全营养配方可冲泡即食棒及其制备方法 | |
| CN107106528A (zh) | 使用丝氨酸治疗或预防炎症 | |
| PT1841330E (pt) | Utilização de fórmula para lactentes com teor proteico reduzido | |
| CN104822279A (zh) | 缓减压力症状的人乳寡糖 | |
| NO340945B1 (no) | Næringsmessig komplett morsmelkerstatning | |
| JP2013511983A (ja) | 高タンパク成分及び外因性ヌクレオチドを含む栄養組成物 | |
| CN106061291A (zh) | 使用绿茶提取物来增加骨骼肌蛋白质合成的方法 | |
| CN118020922A (zh) | 按年龄定制的具有不同蛋白质含量的营养组合物 | |
| CN106659222A (zh) | 肌醇和益生菌及其用途 | |
| TW201332555A (zh) | 在妊娠期間使用特定碳水化合物系統以降低後代後續生命中之不利健康效應 | |
| CN107105751A (zh) | 使用脯氨酸、丝氨酸和苏氨酸促进肠粘膜愈合 | |
| Russ et al. | Post-weaning effects of milk and milk components on the intestinal mucosa in inflammation | |
| KR20220107011A (ko) | 임산부의 미생물총을 개선하기 위한 hmo의 혼합물 | |
| Falcão et al. | Infant Formulas: A Long Story | |
| AU2014314537B2 (en) | Lactoferrin and memory and learning speed in children | |
| CN107073071A (zh) | 含有肽组分的营养补剂和其用途 | |
| RU2306715C1 (ru) | Сухая питательная смесь для диетологического питания | |
| WO2018074415A1 (ja) | たんぱく質効率向上用の組成物 | |
| Rubino et al. | Advances in infant nutrition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190712 Address after: Vevey Applicant after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Applicant before: Nestle Products Technical Assistance Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170829 |
|
| WD01 | Invention patent application deemed withdrawn after publication |